Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this clinical research study is to demonstrate performance of the normalized TB specific lymphocyte response (NTBSLR) in identifying patients with active TB disease. The secondary exploratory objective is to demonstrate that active TB cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based IGRA.
This study will enroll up to 202 subjects (assumes 15 % exclusion/drop-out rate). The target number of subjects is 75 active TB (recruited from subjects presenting at TB clinics) and 100 active TB excluded (recruited from subjects in the community).
All subjects enrolled in this study will be men or women, aged 18 years or older.
Duration: 1 year
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test Arm 1- T-SPOT.TB assay | Test Arm 1: T-SPOT.TB test using density gradient isolation (Leucosep) For each subject recruited in the study, cells will be isolated using Leucosep Tubes and T-Cell Xtend reagent according to package insert. For each subject recruited in the study, the T-SPOT.TB assay will be run according to the assay package insert. | ||
| Test Arm 2-QuantiFERON-TB Gold Plus assay | Test Arm 2: QuantiFERON-TB Gold Plus For each subject recruited in the study, the QuantiFERON-TB Gold Plus (QFT-Plus) assay will be run according to the assay package insert. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| NTBSLR | The primary objective of this study is to demonstrate performance of the normalized Tuberculosis (TB) specific lymphocyte response (NTBSLR) in identifying patients with active Tuberculosis (TB) disease. | 2 year |
| Measure | Description | Time Frame |
|---|---|---|
| IGRA | The secondary exploratory objective is to demonstrate that active Tuberculosis (TB) cannot be identified using an antigen-to-mitogen ratio derived from an ELISA-based Interferon-Gamma Release Assay (IGRA). | 2 year |
Not provided
Subject Inclusion Criteria: Cohort 1A and 1B
Subject inclusion criteria: Cohort 2A and 2B
Subject exclusion criteria: Cohort 2A and 2B
Not provided
Not provided
Not provided
Male and Female 18 years of age and older
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Blanca Restrepo, MD | UTHealth Houston, School of Public Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas Health | Brownsville | Texas | 78520 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D014376 | Tuberculosis |
| ID | Term |
|---|---|
| D009164 | Mycobacterium Infections |
| D000193 | Actinomycetales Infections |
| D016908 | Gram-Positive Bacterial Infections |
| D001424 | Bacterial Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Peripheral blood mononuclear cells (PBMCs) and plasma will be retained and stored at the Lung Infection and Immunity laboratory Biobank for 3 years
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |